Golden ticket

Houston author and consultant opens 'Wonkaland for business' studio and lab

Brad Deutser's Deutser Clarity Institute opens on May 1. Courtesy of DCI

Brad Deutser is taking his approach to business consulting and creative thinking to a whole new level with the Deutser Clarity Institute. The idea accelerator, think tank, and learning lab opens next month in Uptown.

"The Deutser Clarity Institute has captured the imagination of leaders across the country," says Deutser in a release. "Even with the available science on environmental design and leadership learning, we took a chance and pushed creativity and innovation to the farthest reaches to develop a fundamentally different space, way of learning and learning curriculum. We are also producing game changing research which will influence how leaders drive engagement." (Deutser serves on the board of InnovationMap.)

It's the first location for the Houston-based consultancy, which has a diverse staff made up of academicians, business leaders, professional athletes, and more. Deutser — who published his business strategy book, Leading Clarity, last year — has a goal to translate scientific studies and research into immersive education for business leaders. The institute's website describes it as "Wonkaland for business" and is supposed to surround its visitors with an imaginative space for clients' creative exploration.

Here are some design elements you can expect at DCI, according to the release:

  • A 6-by-6-foot glass "Clarity Performance Index"
  • A 10-by-10-foot energy obstruction grid
  • 15 magic spinning cubes (games on two sides, whiteboard on one side and clarity exercise on one side of each cube)
  • A "higher thinking" leadership game/journey on the ceiling
  • A mirrored reflection room with exercises on each mirror and window pane
  • The brain labyrinth
  • A positivity beam
  • A "leadership weave" which is a live research project on leadership competencies by industry.
  • Tactile and engaging tools, like: magnets, stickers, colorful markers, multi-sized sticky notes and more.

Along with its grand opening, DCI is releasing its findings from a study on employee engagement. According to the release, the study analyzed over 13,500 employees in 13 areas that correlate to performance of organizations. Three of the 13 areas — vision + values, leadership, and team capability — have the biggest impact on employee retention and engagement.

InnovationMap is co-hosting the grand opening of the space.

Creative space

Courtesy of DCI

The institute was designed with creativity in mind.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News